CD271+ Mesenchymal Stem Cells As a Possible Infectious Niche for Leishmania Infantum

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2016 Sep 14

PMID 27622907

Citations 10

Authors

Carolina S Lopes

Nada Daifalla

Bikul Das

Valdo Dias da Silva

Antonio Campos-Neto

Affiliations

Soon will be listed here.

Abstract

Visceral leishmaniasis (VL) is a serious and fatal disease. Therapeutic drugs are toxic and non-sterilizing. The etiological agents Leishmania infantum and Leishmania donovani cause active and asymptomatic diseases. Effective drugs to treat VL exist but unfortunately, post-treatment relapses are common. Little is known why drugs are non-sterilizing or how these intracellular pathogens can escape treatment. Here, using a murine model of VL we found that CD271+/Sca1+ bone marrow mesenchymal stem cells (BM-MSCs) are readily infected in vitro and in vivo by L. infantum. Because BM-MSCs express potent drug efflux pumps, e.g., ABCG2 it is possible that this unique intracellular infectious niche could allow L. infantum to escape anti-parasite drugs.

Citing Articles

The Parasitemia has Contributed to the Severity of Cases of Visceral Leishmaniasis.

Campelo C, Medvedovsky A, de Holanda P, de Oliveira D, de Albuquerque-Pinto L, Melo L Indian J Microbiol. 2024; 64(2):511-519.

PMID: 39011003 PMC: 11246353. DOI: 10.1007/s12088-023-01182-6.

Elucidating the role played by bone marrow in visceral leishmaniasis.

Veras P, de Santana M, Brodskyn C, Fraga D, Solca M, De Menezes J Front Cell Infect Microbiol. 2023; 13:1261074.

PMID: 37860064 PMC: 10582953. DOI: 10.3389/fcimb.2023.1261074.

Real-time impact of COVID-19 pandemic on cutaneous leishmaniasis case finding and strategic planning, preventive interventions, control and epidemiology in a region with a high burden of cutaneous leishmaniasis and COVID-19: A cross-sectional....

Shams M, Rashidi A, Mohamadi J, Moradi M, Pakzad R, Naserifar R Health Sci Rep. 2023; 6(8):e1489.

PMID: 37599657 PMC: 10432587. DOI: 10.1002/hsr2.1489.

Unrevealing the Mystery of Latent Leishmaniasis: What Cells Can Host ?.

Valigurova A, Kolarova I Pathogens. 2023; 12(2).

PMID: 36839518 PMC: 9967396. DOI: 10.3390/pathogens12020246.

Delineating the role of extracellular vesicles in cancer metastasis: A comprehensive review.

Majood M, Rawat S, Mohanty S Front Immunol. 2022; 13:966661.

PMID: 36059497 PMC: 9439583. DOI: 10.3389/fimmu.2022.966661.

References

Sugimura R, He X, Venkatraman A, Arai F, Box A, Semerad C . Noncanonical Wnt signaling maintains hematopoietic stem cells in the niche. Cell. 2012; 150(2):351-65. PMC: 4492542. DOI: 10.1016/j.cell.2012.05.041. View

Jang Y, Sharkis S . A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche. Blood. 2007; 110(8):3056-63. PMC: 2018677. DOI: 10.1182/blood-2007-05-087759. View

Campos-Neto A, Suffia I, Cavassani K, Jen S, Greeson K, Ovendale P . Cloning and characterization of a gene encoding an immunoglobulin-binding receptor on the cell surface of some members of the family Trypanosomatidae. Infect Immun. 2003; 71(9):5065-76. PMC: 187365. DOI: 10.1128/IAI.71.9.5065-5076.2003. View

Aggarwal S, Pittenger M . Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2004; 105(4):1815-22. DOI: 10.1182/blood-2004-04-1559. View

Fujisaki J, Wu J, Carlson A, Silberstein L, Putheti P, Larocca R . In vivo imaging of Treg cells providing immune privilege to the haematopoietic stem-cell niche. Nature. 2011; 474(7350):216-9. PMC: 3725645. DOI: 10.1038/nature10160. View

Ankrum J, Ong J, Karp J . Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol. 2014; 32(3):252-60. PMC: 4320647. DOI: 10.1038/nbt.2816. View

Chang K, Dwyer D . Multiplication of a human parasite (Leishmania donovani) in phagolysosomes of hamster macrophages in vitro. Science. 1976; 193(4254):678-80. DOI: 10.1126/science.948742. View

Bogdan C, Donhauser N, Doring R, Rollinghoff M, Diefenbach A, Rittig M . Fibroblasts as host cells in latent leishmaniosis. J Exp Med. 2000; 191(12):2121-30. PMC: 2193203. DOI: 10.1084/jem.191.12.2121. View

Alvarez-Viejo M, Menendez-Menendez Y, Otero-Hernandez J . CD271 as a marker to identify mesenchymal stem cells from diverse sources before culture. World J Stem Cells. 2015; 7(2):470-6. PMC: 4369502. DOI: 10.4252/wjsc.v7.i2.470. View

10.

Das B, Antoon R, Tsuchida R, Lotfi S, Morozova O, Farhat W . Squalene selectively protects mouse bone marrow progenitors against cisplatin and carboplatin-induced cytotoxicity in vivo without protecting tumor growth. Neoplasia. 2008; 10(10):1105-19. PMC: 2546596. DOI: 10.1593/neo.08466. View

11.

Kuci S, Kuci Z, Kreyenberg H, Deak E, Putsch K, Huenecke S . CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties. Haematologica. 2010; 95(4):651-9. PMC: 2857196. DOI: 10.3324/haematol.2009.015065. View

12.

Gallacher L, Murdoch B, Wu D, Karanu F, Keeney M, Bhatia M . Isolation and characterization of human CD34(-)Lin(-) and CD34(+)Lin(-) hematopoietic stem cells using cell surface markers AC133 and CD7. Blood. 2000; 95(9):2813-20. View

13.

Sundar S, Chakravarty J . An update on pharmacotherapy for leishmaniasis. Expert Opin Pharmacother. 2014; 16(2):237-52. PMC: 4293334. DOI: 10.1517/14656566.2015.973850. View

14.

Raghuvanshi S, Sharma P, Singh S, Van Kaer L, Das G . Mycobacterium tuberculosis evades host immunity by recruiting mesenchymal stem cells. Proc Natl Acad Sci U S A. 2010; 107(50):21653-8. PMC: 3003090. DOI: 10.1073/pnas.1007967107. View

15.

Tormin A, Li O, Brune J, Walsh S, Schutz B, Ehinger M . CD146 expression on primary nonhematopoietic bone marrow stem cells is correlated with in situ localization. Blood. 2011; 117(19):5067-77. PMC: 3109533. DOI: 10.1182/blood-2010-08-304287. View

16.

Lv F, Tuan R, Cheung K, Leung V . Concise review: the surface markers and identity of human mesenchymal stem cells. Stem Cells. 2014; 32(6):1408-19. DOI: 10.1002/stem.1681. View

17.

Rasmusson I, Uhlin M, Le Blanc K, Levitsky V . Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes. J Leukoc Biol. 2007; 82(4):887-93. DOI: 10.1189/jlb.0307140. View

18.

Timper K, Seboek D, Eberhardt M, Linscheid P, Christ-Crain M, Keller U . Human adipose tissue-derived mesenchymal stem cells differentiate into insulin, somatostatin, and glucagon expressing cells. Biochem Biophys Res Commun. 2006; 341(4):1135-40. DOI: 10.1016/j.bbrc.2006.01.072. View

19.

Rittig M, Bogdan C . Leishmania-host-cell interaction: complexities and alternative views. Parasitol Today. 2000; 16(7):292-7. DOI: 10.1016/s0169-4758(00)01692-6. View

20.

Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D . Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006; 8(4):315-7. DOI: 10.1080/14653240600855905. View